Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-01-28 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物关于变更办公地址的公告
Regulatory Filings Classification · 100% confidence The document is a short announcement about the change of the company's office address. It contains no financial data, no regulatory form references, no meeting or voting information, and no detailed report content. It is a general corporate announcement about administrative changes. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other specific categories.
2022-01-28 Chinese
前沿生物关于2021年度业绩预告的公告
Earnings Release Classification · 95% confidence The document is a 2021 annual performance forecast (业绩预告) for the company 前沿生物药业（南京）股份有限公司. It provides estimated financial results for the full fiscal year 2021, including revenue, net profit, and R&D expenses, but explicitly states that the forecast has not been audited. The document is relatively short (2351 characters) and serves as a preliminary earnings outlook rather than a full financial report. It does not contain actual audited financial statements or detailed financial analysis. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or annual financial results highlights or forecasts. FY 2021
2022-01-28 Chinese
前沿生物药业（南京）股份有限公司实际控制人：关于前沿生物药业（南京）股份有限公司股票交易异常波动问询函的回函
Regulatory Filings Classification · 95% confidence The document is a response letter from the actual controller of a company addressing an inquiry about abnormal stock trading fluctuations. It explicitly states there are no undisclosed major matters affecting stock trading and no insider trading during the period. The content is a regulatory response to a stock exchange inquiry rather than a financial report, management change, or other specific filings. The document is short (374 characters) and serves as a formal reply to a regulatory inquiry, fitting best under Regulatory Filings (RNS).
2022-01-17 Chinese
前沿生物股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by a company listed on the Shanghai Stock Exchange. It discusses the stock price movement over three consecutive trading days, references regulatory rules from the Shanghai Stock Exchange, and provides explanations and risk warnings related to the stock price volatility. It does not contain financial statements, earnings data, or detailed financial analysis. It is a regulatory announcement about stock price behavior and related disclosures, not a financial report or earnings release. Therefore, it fits best into the category of Regulatory Filings (RNS). The document length is 4079 characters, which is relatively short and consistent with an announcement rather than a full report.
2022-01-17 Chinese
前沿生物关于股东权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a short announcement (2200 characters) about a shareholder's equity change, specifically a reduction in shareholding by a shareholder named Shanghai Zhongcheng Hongyun Business Consulting Service Partnership. It details the shareholding before and after the change, confirms no change in controlling shareholders or actual controllers, and references a simplified equity change report filed on the Shanghai Stock Exchange website. There is no financial data, no detailed report content, and the document serves as a notification of a change in major shareholding below the 5% threshold. This fits the definition of a Major Shareholding Notification (MRQ).
2022-01-07 Chinese
前沿生物简式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the reduction of shareholding by the information disclosure obligor, Shanghai Zhongcheng Hongyun Business Information Consulting Service Partnership, in the listed company Qianyan Biopharmaceutical (Nanjing) Co., Ltd. The document includes specifics about the shareholding before and after the change, the method of reduction (block trade), dates, and legal compliance statements. It is a formal disclosure of a change in major shareholding, specifically a reduction below the 5% threshold. There are no financial statements or earnings data, nor is it an announcement of a meeting or voting results. The content fits the definition of a Major Shareholding Notification (MRQ) as it reports a change in significant share ownership levels crossing a threshold (from above 5% to below 5%). The document length is about 5408 characters, which is sufficient for a full report of this type, not just an announcement of a report. Therefore, the correct classification is MRQ with high confidence.
2022-01-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.